NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 1 filers reported holding NUVECTIS PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93,865 | +982.4% | 7,282 | +1241.1% | 0.00% | – |
| Q2 2023 | $8,672 | +288966.7% | 543 | +117.2% | 0.00% | – |
| Q1 2023 | $3 | -70.0% | 250 | -81.6% | 0.00% | – |
| Q4 2022 | $10 | -100.0% | 1,359 | -66.5% | 0.00% | – |
| Q3 2022 | $29,000 | +107.1% | 4,052 | +216.8% | 0.00% | – |
| Q2 2022 | $14,000 | +7.7% | 1,279 | -26.9% | 0.00% | – |
| Q1 2022 | $13,000 | – | 1,750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FORBES J M & CO LLP | 67,000 | $1,070 | 0.13% |
| BALDWIN BROTHERS LLC/MA | 90,061 | $1,438,274 | 0.12% |
| Dorsey Wright & Associates | 1,444 | $23,061 | 0.01% |
| EDMOND DE ROTHSCHILD HOLDING S.A. | 22,820 | $364,435 | 0.01% |
| HOLLENCREST CAPITAL MANAGEMENT | 3,040 | $48,549 | 0.01% |
| Renaissance Technologies | 36,400 | $581 | 0.00% |
| MARSHALL WACE, LLP | 41,775 | $667,147 | 0.00% |
| UBS Group AG | 3,979 | $63,545 | 0.00% |
| RHUMBLINE ADVISERS | 6,778 | $108,244 | 0.00% |
| FMR LLC | 24 | $383 | 0.00% |